Stay updated on Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial
Sign up to get notified when there's something new on the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page.

Latest updates to the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.5.0 to the history and removed Revision: v3.4.3.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedNew revision entry v3.4.3 is added and v3.4.2 is removed from the study record history.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision: v3.4.2 was added to the history. Notices about government funding and operating status were removed.SummaryDifference0.8%

- Check64 days agoChange DetectedA site-wide funding-status notice was added and the record history shows Revision v3.4.1, replacing Revision v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check71 days agoChange DetectedUI updates include a new Show glossary option and explanations of the color-coded change highlights (green for additions and red for deletions) with a new revision tag (v3.4.0) visible on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check85 days agoChange DetectedA new revision entry (v3.3.4) was added to the history and the previous revision (v3.3.3) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page.